WordNet
- write by means of a keyboard with types; "type the acceptance letter, please" (同)typewrite
- a small metal block bearing a raised character on one end; produces a printed character when inked and pressed on paper; "he dropped a case of type, so they made him pick them up"
- (biology) the taxonomic group whose characteristics are used to define the next higher taxon
- a subdivision of a particular kind of thing; "what type of sculpture do you prefer?"
- all of the tokens of the same symbol; "the word `element contains five different types of character"
- printed characters; "small type is hard to read"
- identify as belonging to a certain type; "Such people can practically be typed" (同)typecast
- a soft thin (usually translucent) paper (同)tissue_paper
- part of an organism consisting of an aggregate of cells having a similar structure and function
- (biology) any agency bringing about activation; a molecule that increases the activity of an enzyme or a protein that increases the production of a gene product in DNA transcription
- an inactive form of plasmin that occurs in plasma and is converted to plasmin by organic solvents
- writing done with a typewriter (同)typewriting
PrepTutorEJDIC
- 〈C〉(…の)『型』,タイプ,類型,種類(kind)《+of+名》 / 〈C〉(その種類の特質を最もよく表している)『典型』,手本,模範《+of+名》 / 〈U〉《集合的に》活字;〈C〉(1個の)活字 / 〈U〉(印刷された)字体,活字 / 〈C〉(貨幣・メダルなどの)模様,図柄 / 〈C〉血液型(blood group) / …‘を'タイプに打つ / (…として)…‘を'分類する《+名+as+名(doing)》 / …‘の'型を決める / タイプライターを打つ
- 〈U〉〈C〉(生物体の)『組織』 / 〈U〉〈C〉『薄織物』 / 〈U〉〈C〉水を吸収する柔らかな薄紙 / 〈C〉カーボンコピー用薄紙 / 〈C〉《a ~》(…を)織り交ぜて作ったもの《+of+名》 / =tissue paper
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 急性虚血性脳卒中に対する再灌流療法 reperfusion therapy for acute ischemic stroke
- 2. 止血の概要 overview of hemostasis
- 3. 急性虚血性脳卒中における経静脈的線維素溶解（血栓溶解）治療：治療的使用 intravenous fibrinolytic thrombolytic therapy in acute ischemic stroke therapeutic use
- 4. ST上昇型心筋梗塞における血栓溶解療法の特性および臨床試験 characteristics of fibrinolytic thrombolytic agents and clinical trials in acute st elevation myocardial infarction
- 5. Central catheters for acute and chronic hemodialysis access
English Journal
- New antiplatelet agents prescribed to patients with ischemic heart disease: implications for treatment of stroke.
- Thomas K1, Kessler C.Author information 1Jesse Brown VAMC, 820 S. Damen Ave, Chicago, IL, 60612, USA, Kurian.thomas@va.gov.AbstractOPINION STATEMENT: Stroke continues to be a significant public health problem worldwide. Despite a number of clinical trials testing various therapeutic agents, we are still left with a small armamentarium of options. Aspirin, clopidogrel and combination aspirin-dipyridamole remain the mainstay for prevention of recurrent ischemic stroke. Tissue plasminogen activator (tPA) or alteplase is the sole agent used in the acute phase up to 4.5 h from the onset of stroke symptoms. A greater understanding of pathophysiologic mechanisms produced an array of acute experimental treatments including intravenous magnesium and free radical scavengers. However, they did not stand up to the scrutiny of phase III randomized clinical trials. Secondary prevention of stroke benefitted more from epidemiologic studies focusing on risk factor modifications, rather than antiplatelet or other stroke specific agents. One must ask if new treatments for stroke are exhausted. Despite the frustrations of stroke neurologists, new avenues for treatment continue to be explored. One comes from our colleagues in cardiology. Development of new medications for treating ischemic heart disease, acute or chronic, may provide opportunity to cross over into stroke. Cardiovascular trials usually encompass stroke as an outcome measure. As of yet, there have not been the data to support use of these agents in stroke. Recent medications for acute and chronic phases of ischemic heart diseases include desmoteplase, tenecteplase, tirofiban, prasugrel, and ticagrelor. Though some of these medications may fail to show a benefit in stroke patients, we feel there is always potential for a breakthrough.
- Current treatment options in neurology.Curr Treat Options Neurol.2014 May;16(5):289. doi: 10.1007/s11940-014-0289-2.
- OPINION STATEMENT: Stroke continues to be a significant public health problem worldwide. Despite a number of clinical trials testing various therapeutic agents, we are still left with a small armamentarium of options. Aspirin, clopidogrel and combination aspirin-dipyridamole remain the mainstay for
- PMID 24619768
- Stroke units in Italy: engaging the public in optimizing existing resources.
- Baldereschi M1, Di Carlo A, Vaccaro C, Toni D, Polizzi B, Inzitari D; Promotion and Implementation of Stroke Care in Italy Project Working Group.Author information 1Italian National Research Council, Institute of Neuroscience, Florence, Italy.AbstractBACKGROUND AND PURPOSE: The lack of a wide implementation of stroke units (SU)s in Italy appears to accompany the underuse of the operating units. Community awareness of acute stroke care options may affect stroke resource use. Our aim was to determine the level of knowledge about SUs and tissue-plasminogen activator (t-PA) treatment amongst Italian adults and investigate its relationship to local stroke services implementation.
- European journal of neurology : the official journal of the European Federation of Neurological Societies.Eur J Neurol.2014 May;21(5):791-6. doi: 10.1111/ene.12395. Epub 2014 Mar 6.
- BACKGROUND AND PURPOSE: The lack of a wide implementation of stroke units (SU)s in Italy appears to accompany the underuse of the operating units. Community awareness of acute stroke care options may affect stroke resource use. Our aim was to determine the level of knowledge about SUs and tissue-pla
- PMID 24602205
- Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors.
- Tran HT1, Sørensen B, Rea CJ, Bjørnsen S, Ueland T, Pripp AH, Tjønnfjord GE, Holme PA.Author information 1Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Haematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.AbstractHaemophilia patients with inhibitors require bypassing agents (BPA) like activated prothrombin complex concentrate (aPCC) and recombinant activated factor VII (rFVIIa) to control bleeds. Adjunct tranexamic acid (TXA) may improve haemostasis. The objective of this study was to investigate safety and haemostatic effect of TXA given in combination with BPA. Healthy volunteers (N = 5) and haemophilia inhibitor patients (N = 6) were enrolled in a prospective case crossover design. Controls were treated with TXA 20 mg kg(-1) orally (O.R.) Patients were treated with aPCC 75 IU kg(-1) intravenous (I.V.) on day 1 followed by TXA 20 mg kg(-1) O.R. combined with aPCC 75 IU kg(-1) I.V. on day 2. A 14-day washout occurred before crossover to rFVIIa 90 μg kg(-1) I.V. ±TXA. Safety evaluation and blood sampling processes were performed at baseline, 15, 30, 60, 120, 180 and 240 min post treatment. Primary outcome was maximum clot firmness (MCF) evaluated by whole blood thromboelastometry using a TF + tissue plasminogen activator-based assay. Healthy controls showed a 20-fold increase in MCF following TXA. Adjunct TXA to aPCC or rFVIIa induced a significant increase in MCF (P < 0.0001) reaching levels indistinguishable from healthy controls treated with TXA (P > 0.05). Infusion of aPCC or rFVIIa alone induced only 3-10 fold increase in MCF from baseline, with a decline in MCF starting after 60-120 min. TXA did not increase the endogenous thrombin potential. No clinical or laboratory signs of thromboembolic events, disseminated intravascular coagulation, or hypercoagulability were observed. Combination of aPCC or rFVIIa with TXA normalizes clot stability in haemophilia patients with inhibitor as compared to healthy controls. No clinical or laboratory adverse events were observed.
- Haemophilia : the official journal of the World Federation of Hemophilia.Haemophilia.2014 May;20(3):369-75. doi: 10.1111/hae.12318. Epub 2013 Nov 19.
- Haemophilia patients with inhibitors require bypassing agents (BPA) like activated prothrombin complex concentrate (aPCC) and recombinant activated factor VII (rFVIIa) to control bleeds. Adjunct tranexamic acid (TXA) may improve haemostasis. The objective of this study was to investigate safety and
- PMID 24251535
Japanese Journal
- 臨床病理カンファレンス(36)脳梗塞
- 露口 尚弘,伊倉 義弘,西尾 明正 [他]
- 綜合臨床 60(5), 791-799, 2011-05
- NAID 40018826581
- Novel Situations of Endothelial Injury in Stroke — Mechanisms of Stroke and Strategy of Drug Development: Intracranial Bleeding Associated With the Treatment of Ischemic Stroke: Thrombolytic Treatment of Ischemia-Affected Endothelial Cells With Tissue-Type Plasminogen Activator
- Suzuki Yasuhiro,Nagai Nobuo,Umemura Kazuo
- Journal of Pharmacological Sciences 116(1), 25-29, 2011
- … On the basis of clinical trials, only tissue-type plasminogen activator (t-PA) has been approved for treating acute ischemic strokes, but delayed treatment with t-PA is associated with the risk of cerebral hemorrhagic transformation of ischemic stroke. …
- NAID 130000663524
Related Links
- Rijken DC (1988). "Relationships between structure and function of tissue-type plasminogen activator". Klin. Wochenschr. 66 Suppl 12: 33–9. PMID 3126346. Bode W, Renatus M (1997). "Tissue-type plasminogen activator: variants ...
- Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation ...
Related Pictures
★リンクテーブル★
| リンク元 | 「組織プラスミノゲンアクチベータ」「組織型プラスミノーゲン活性化因子」「組織型プラスミノゲンアクチベーター」「組織型プラスミノーゲンアクチベーター」「組織プラスミノゲンアクチベーター」 |
| 関連記事 | 「type」「activator」「typed」「typing」「plasminogen activator」 |
「組織プラスミノゲンアクチベータ」
- 英
- tissue plasminogen activator t-PA, recombinant tissue plasminogen activator, tissue-type plasminogen activator
- 同
- 組織性プラスミノゲン活性化因子
「組織型プラスミノーゲン活性化因子」
「組織型プラスミノゲンアクチベーター」
「組織型プラスミノーゲンアクチベーター」
「組織プラスミノゲンアクチベーター」
「type」
- n.
- (windows)ファイル内容表示(linux -> cat])
- ex. type report_20111118.jp.htm | php a.php > report_20111118.jp.jp.jp.html
「activator」
- n.
「typed」
- adj.
- 型の
「typing」
- n.
- タイプで打つこと、タイピング。分類